The frequency of RAC1 P29S mutation (overall RAC1 P29S mutation of 4.1%) was found to be more prevalent in male patients and similar between primary (9.2%) and metastatic tumors (8.6%) (Krauthammer et al., 2012). Here, RAC1 is linked to metastatic neoplasm.